Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9099622 | 0.99 | ALDH1A1 (0.55) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| Avanbulin SCHEMBL1160317 | 0.93 | KDM4E (0.56) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| Avanbulin SCHEMBL29374555 | 0.93 | KDM4E (0.56) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| Avanbulin SCHEMBL9099635 | 0.92 | KDM4E (0.55) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL18791198 | 0.92 | ALDH1A1 (0.59) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL1384956 | 0.91 | ALDH1A1 (0.56) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL1384874 | 0.91 | ALDH1A1 (0.56) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL1383969 | 0.90 | KDM4E (0.56) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL1386947 | 0.89 | ALDH1A1 (0.56) | ALDH1A1KDM4EHSD17B10HPGDTSHR | |
| SCHEMBL13449696 | 0.88 | SMN1; SMN2 (0.54) | ALDH1A1KDM4EHSD17B10HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633383-B2 | Dosage principle for drugs useful for treating neoplastic diseases | Basilea Pharmaceutica International AG (CH) | 2023-04-25 | — | — | US | disclosed |
| US-11419856-B2 | Pharmaceutical combinations for use in the treatment of neoplastic diseases | Basilea Pharmaceutica International AG (CH) | 2022-08-23 | — | — | US | disclosed |
| US-20220031670-A1 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | BASILEA PHARM INT AG (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20200390749-A1 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | BASILEA PHARM INT AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-20200237730-A1 | NOVEL DOSAGE PRINCIPLE FOR DRUGS USEFUL FOR TREATING NEOPLASTIC DISEASES | Basilea Pharmaceutica International AG (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10724072-B2 | Use of phospho-Akt as a biomarker of drug response | BASILEA PHARMACEUTICA AG (CH) | 2020-07-28 | — | — | US | disclosed |
| US-10656162-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2020-05-19 | — | — | US | disclosed |
| US-10222377-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2019-03-05 | — | — | US | disclosed |
| US-20190010536-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | BASILEA PHARMACEUTICA AG (CH) | 2019-01-10 | — | — | US | disclosed |
| US-20180364254-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG | 2018-12-20 | — | — | US | disclosed |
| US-20140005237-A1 | USE OF ACETYLATED TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-20130345263-A1 | USE OF STATHMIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2013-12-26 | — | — | US | disclosed |
| EP-2666015-A1 | USE OF STATHMIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | Basilea Pharmaceutica AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| EP-2666014-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | Basilea Pharmaceutica AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| EP-2666016-A1 | USE OF BUBR1 AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | Basilea Pharmaceutica AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | BASILEA PHARMACEUTICA AG | 2012-10-18 | — | — | US | disclosed |
| WO-2012113802-A1 | USE OF ACETYLATED TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012098207-A1 | USE OF BUBR1 AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098203-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098208-A1 | USE OF STATHMIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10724072-B2 | Use of phospho-Akt as a biomarker of drug response | AKT3, AKT1S1, AKT2 | ALDH1A1 4829/4885KDM4E 3884/4885HSD17B10 2197/4885 |
| US-20120264792-A1 | FURAZANOBENZIMIDAZOLES AS PRODRUGS TO TREAT NEOPLASTIC OR AUTOIMMUNE DISEASES | SSB, VHL, AHR | ALDH1A1 838/4885KDM4E 926/4885HSD17B10 701/4885 |
| US-10656162-B2 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles | TUBB, TUBB1, TUBB6 | ALDH1A1 1153/4885KDM4E 4206/4885HSD17B10 2199/4885 |
| US-20180364254-A1 | USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | TUBB, TUBB1, TUBB6 | ALDH1A1 1153/4885KDM4E 4206/4885HSD17B10 2199/4885 |
| US-11633383-B2 | Dosage principle for drugs useful for treating neoplastic diseases | SLC5A11, SLC10A1, SLC10A2 | ALDH1A1 574/4885KDM4E 2532/4885HSD17B10 713/4885 |
| US-20200390749-A1 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | ERLIN1, EDNRB, ERLIN2 | ALDH1A1 838/4885KDM4E 4438/4885HSD17B10 894/4885 |
| US-11419856-B2 | Pharmaceutical combinations for use in the treatment of neoplastic diseases | ERLIN1, EDNRB, ERLIN2 | ALDH1A1 838/4885KDM4E 4438/4885HSD17B10 894/4885 |
| US-20190010536-A1 | USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE | AKT3, AKT1S1, AKT2 | ALDH1A1 4829/4885KDM4E 3884/4885HSD17B10 2197/4885 |
| US-20130345263-A1 | USE OF STATHMIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES | STMN1, STMN2, MYADM | ALDH1A1 2097/4885KDM4E 3432/4885HSD17B10 2804/4885 |
| US-10222377-B2 | Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles | BUB1B, BUB1, BUB3 | ALDH1A1 1640/4885KDM4E 2211/4885HSD17B10 1484/4885 |
| US-20200237730-A1 | NOVEL DOSAGE PRINCIPLE FOR DRUGS USEFUL FOR TREATING NEOPLASTIC DISEASES | SLC10A1, SLC10A2, SLC5A11 | ALDH1A1 846/4885KDM4E 2492/4885HSD17B10 853/4885 |
| US-20220031670-A1 | PHARMACEUTICAL COMBINATIONS FOR USE IN THE TREATMENT OF NEOPLASTIC DISEASES | KRAS, GLS, SLC28A1 | ALDH1A1 358/4885KDM4E 4124/4885HSD17B10 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.